SNX19

Across TCGA pan-cancer cohorts, SNX19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SNX19 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SNX19 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNX19 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and OV show a favorable association.

PDAC, CCRCC, and OV are the cancer types where SNX19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.211	0.509	.022	7	view →
CCRCC	OS	Quartile	II,III,IV	1.000	0.583	.015	5	view →
OV	DFS	Median	All	1.000	0.657	.018	4	view →
LSCC	OS	Median	II,III,IV	0.619	0.886	.017	4	view →
HNSC	OS	Quartile	All	0.751	1.000	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SNX19–PDAC (DFS)

Open the PDAC breakdown →